|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2015-11-20 17:17 编辑
Hep DART 2015
TUESDAY, DECEMBER 8, 2015(continued)
EVENING SESSION15:30–17:00
Poster Session 17:00
Review of Poster Presentations
Adrian Di Bisceglie;
Saint Louis University School of Medicine, USA
Matthias Götte
University of Alberta, Canada
THE TIDE HAS SHIFTED TOWARD HBV CURE AND TREATMENT FOR NASH
Chairs:
Patrizia Farci; National Institutes of Health, USA
Stanley Lemon;
University of North Carolina at Chapel Hill, USA
17:50
Using CRISPR/C as to Cure Chronic HBV Infections
Bryan Cullen; Duke University Medical Center, USA
18:10
Efficient Liver Targeting and Uptake by Novel Tenofovir Prodrug, CMX157, For the Treatment of Hepatitis B
John Sullivan-Bὀlyai; ContraVir Pharmaceuticals, Inc., USA
18:20
Cyclophilin Inhibitors and Their Potential as Therapeutics for the Treatment of HBV
Michael Sofia; Arbutus Biopharma Corporation,USA
18:30
Preclinical and Clinical Profile of NVR 3-778, a First-In-Class HBV Core Inhibitor for the Treatment of Chronic Hepatitis B
Osvaldo Flores; Novira Therapeutics,USA
18:40
New Insights on HBV Biology from the ARC-520 Development Program
Bruce Given;Arrowhead Research Corporation, USA
18:50
Cenicriviroc: A Novel Agent Targeting Immuno-Inflammatory Pathways for the Treatment of NASH with Liver Fibrosis
Eric Lefebvre;Tobira Therapeutics, Inc., USA
19:00
RG-101, a Novel microRNA Therapeutic to Target the Host Factor of HCV
Paul Grint; Regulus Therapeutics, USA
19:10
The Clinical Stage Molecule Birinanant Can Harness Endogenous TNF to Kill HBV Infected Hepatocytes and Clear Infection in a Preclinical Model
Marc Pellegrini; The Walter and Eliza Hall Institute of Medical Research, Australia |
|
发表于 2015-11-20 16:28
